In support of this argument, bispecific constructs that guide anti-CD40 to the tumor microenvironment were developed to minimize off-target toxicity and have showed some preclinical efficacy (Rigamonti et al., 2019, Ye et al., 2019). Here, CD40 is linked to neoplasm.